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INTRODUCTION  
Patients with squamous cell carcinoma of the head and neck (SCCHN) frequently present with advanced 
disease and receive combined modality therapy [1]. Unfortunately, 10–15% of patients progress within 6 
months of platinum-based therapy and have a poor prognosis, with no established standard of care [2-5]. 
The CheckMate 141 trial investigated nivolumab vs investigator’s choice (IC) of therapy in patients with 
recurrent or metastatic (R/M) SCCHN. Eligible patients had experienced tumor progression or recurrence 
within 6 months of platinum-based chemotherapy administered in the locally advanced, recurrent, or 
metastatic disease setting. Nivolumab significantly extended overall survival (OS) compared with IC 
(hazard ratio [HR], 0.70; 97.73% confidence interval [CI], 0.51–0.96; p = .01) in the overall study 
population [6]. Here, we report outcomes among patients who received nivolumab vs. IC as first-line 
treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the 
adjuvant or primary (i.e., with radiation) setting, hereafter referred to as first-line treatment for R/M 
SCCHN. Updated results with longer follow-up in the overall population are also reported. 
 
METHODS 
In the randomized, open-label, phase III CheckMate 141 (NCT02105636) trial [6], patients were 
randomized 2:1 to nivolumab (3 mg/kg every 2 weeks) or IC (methotrexate, docetaxel, or cetuximab). 
The primary endpoint was OS; additional endpoints included progression-free survival (PFS), objective 
response rate (ORR; per Response Evaluation Criteria In Solid Tumors version 1.1), and safety [6]. In the 
present post hoc analysis, efficacy and safety were assessed in patients receiving nivolumab vs IC as first-
line treatment for R/M SCCHN. Updated results in the overall intent-to-treat population, based on a 
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database lock of September 2016, are also reported. Cox proportional hazards models were used to 
estimate HRs and CIs. 
CheckMate 141 was registered with the National Cancer Institute and approved by the 
institutional board at each participating site. All patients provided informed consent prior to enrollment. 
 
RESULTS 
First-line Treatment for R/M SCCHN 
In all, 78 patients (21.6%) received nivolumab (n = 52) or IC (n = 26) as first-line treatment for R/M 
SCCHN. The baseline characteristics of these patients (Supplemental Table 1) were similar to those of the 
overall population [6].  
Nivolumab as first-line treatment improved OS vs. IC in patients with R/M SCCHN (median 
[95% CI], 7.7 [3.1–13.8] vs. 3.3 [2.1–6.4] months; HR [95% CI], 0.56 [0.33–0.95]) (Fig. 1). The 12-
month OS rate was 39.2% vs. 15.4%, respectively. Median (95% CI) PFS was 2.3 (1.9–3.3) months for 
nivolumab and 2.3 (1.7–3.2) months for IC; HR, 0.81; 95% CI, 0.48–1.37. The ORR was 19.2% vs. 
11.5%, respectively; time to response was 2.0 months in both arms (Supplemental Table 2). Grade 3–4 
treatment-related adverse event (TRAE) rates were 27.5% for nivolumab and 32.0% for IC (Supplemental 
Table 3).  
 
One-Year Follow-up in the Overall Intent-to-Treat Population 
With a minimum follow-up of 11.4 months, 16/240 patients (7%) in the nivolumab arm and 1/121 
patients (1%) in the IC arm in the intent-to-treat population were still on treatment (Supplemental Fig. 1). 
Median (range) duration of therapy was 1.9 (0–24+) months for nivolumab and 1.9 (0–12+) months for 
4 
 
This article is protected by copyright. All rights reserved.
Gillison et al. HIGHLY CONFIDENTIAL  
IC. Nivolumab continued to improve OS vs. IC significantly (Fig. 2), with the 18-month OS rate nearly 
tripled (21.5% vs. 8.3%). OS among subgroups was generally consistent with overall treatment effect 
(Supplemental Fig. 2). Median (95% CI) PFS was 2.0 (1.9–2.1) months for nivolumab and 2.3 (2.0–3.1) 
months for IC; HR, 0.87; 95% CI, 0.69–1.11. ORR did not change from the initial analysis [6]; six 
patients in the nivolumab arm and one patient in the IC arm had a complete response and were alive at 
last follow-up. As of database lock, three patients were off-study and four patients still on-study had not 
progressed. Median (range) time to response was 2.1 (1.8–7.4) months for nivolumab vs. 2.0 (1.9–4.6) 
months for IC. Median (range) duration of response was 9.7 (2.8–20.3+) months vs. 4.0 (1.5+–8.5+) 
months, respectively.  
TRAEs in the overall treated population in the 1-year follow-up were consistent with the initial 
analysis; longer follow-up identified no new safety signals. Grade 3–4 TRAE rates were 15.3% for 
nivolumab vs. 36.0% for IC (Supplemental Table 4). Select endocrine TRAEs were more frequent with 
nivolumab than with IC; none was grade 3–4. Skin-related TRAEs were the most common select TRAEs 
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DISCUSSION 
Consistent with outcomes in the overall patient population of CheckMate 141, nivolumab as first-line  
treatment improved OS and ORR compared with IC in patients with R/M SCCHN. PFS was similar with 
nivolumab vs. IC, as were rates of high-grade TRAEs. Nivolumab is the only agent to significantly 
improve survival in a randomized phase III trial for platinum-refractory R/M SCCHN. With a minimum 
follow-up of 11.4 months in the present analysis, efficacy and safety in the overall intent-to-treat 
population were similar to results at earlier time points [6].  
The current standard of care for first-line treatment of platinum-eligible R/M SCCHN is the 
EXTREME regimen; however, patients with platinum-refractory SCCHN were not included in the 
EXTREME trial. Patients eligible for CheckMate 141, who were platinum-refractory due to progression 
within 6 months of treatment in the primary setting, are generally not candidates for platinum-containing 
therapies such as EXTREME [7]. Their treatment options are limited to methotrexate, taxanes, or 
cetuximab—the IC options in the CheckMate 141 trial. Nivolumab as first-line treatment for R/M 
SCCHN resulted in a 12-month OS of 39% in patients with platinum-refractory disease. Furthermore, 
quality-of-life benefits were observed with nivolumab vs. IC in CheckMate 141 [8].   
Although these data represent a small subgroup of patients, the results support the use of 
nivolumab as first-line therapy for patients with R/M SCCHN who progressed within 6 months of 
platinum-based therapy in the adjuvant or primary setting. CheckMate 714 (NCT02823574) is an 
ongoing, randomized, double-blind, phase II study designed to evaluate the clinical benefit of adding 
anti–CTLA-4 targeted therapy (ipilimumab) to nivolumab for patients with platinum-refractory or 
platinum-eligible R/M SCCHN [9]. Nivolumab plus ipilimumab is being evaluated in CheckMate 651 as 
first-line therapy for platinum-eligible R/M disease vs. EXTREME (NCT02741570) [10].  
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FIGURE LEGENDS 
Figure 1. OS (A) and treatment effect on OS (B) among patients randomized to nivolumab or IC as first-
line treatment for R/M SCCHN after progressing on or after platinum therapy (within 6 months) in the 
adjuvant or primary (i.e., with radiation) setting for locally advanced disease.  
Abbreviations: CI, confidence interval; HPV, human papillomavirus; HR, hazard ratio; IC, 
investigator’s choice; NE, not estimable; Nivo, nivolumab; OS, overall survival; R/M, recurrent 
or metastatic; SCCHN, squamous cell carcinoma of the head and neck.  
 
Figure 2. OS in the overall intent-to-treat population.  
Abbreviations: CI, confidence interval; HR, hazard ratio; IC, investigator’s choice; Nivo, 
nivolumab; OS, overall survival. 
 
Supplemental Figure 1. CONSORT diagram.  
Abbreviations: R/M, recurrent or metastatic; SCCHN, squamous cell carcinoma of the head and 
neck. 
 
Supplemental Figure 2. Treatment effect on overall survival by subgroup for the overall intent-to-treat 
population.  
aStratification factor. 
Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group 
performance status; HPV, human papillomavirus; HR, hazard ratio; IC, investigator’s choice; 
Nivo, nivolumab.   
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SUPPLEMENTARY DATA 
Supplemental Table 1. Baseline characteristics among patients randomized to nivolumab or investigator’s choice 
as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck after progressing on 




(n = 52) 
Investigator’s choice 
(n = 26) 
Age, median (range), years 57.5 (30–79) 59.5 (28–78) 
Age ≥65 years, n (%) 13 (25.0) 9 (34.6) 
Male, n (%) 41 (78.8) 21 (80.8) 















Region, n (%) 
North America 
Europe 





















ECOG performance status, n (%)   
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Characteristics 
Nivolumab 
(n = 52) 
Investigator’s choice 


































aHPV status testing only required for patients with oropharyngeal cancer.  
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Supplemental Table 2. Response among patients receiving nivolumab or investigator’s choice as first-line 
treatment for recurrent or metastatic squamous cell carcinoma of the head and neck after progressing on or after 




(n = 52) 
Investigator’s choice 
(n = 26) 





Unable to determine 
 

















Odds ratio (95% CI) 1.83 (0.46–7.31)  
Time to response, median (range), months 2.0 (1.8–6.3) 2.0 (1.9–4.6) 
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Supplemental Table 3. Most common TRAEs (≥10% in any arm) and select TRAEs among patients receiving 
nivolumab or investigator’s choice as first-line treatment for recurrent or metastatic squamous cell carcinoma of the 
head and neck after progressing on or after platinum therapy (within 6 months) in the adjuvant or primary (i.e., with 
radiation) setting for locally advanced disease. 
Patients, n (%) 
Nivolumab 
(n = 51) 
Investigator’s choice 
(n = 25) 
Any grade Grade 3–4 Any grade Grade 3–4 























































































This article is protected by copyright. All rights reserved.
Gillison et al. HIGHLY CONFIDENTIAL  
aIncludes 1 grade 5 event of pneumonia.  
Abbreviation: TRAE, treatment-related adverse event.  
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Supplemental Table 4. Most common TRAEs (≥10% in any arm) and select TRAEs in the overall treated 
population. 
Patients, n (%) 
Nivolumab 
(n = 236) 
Investigator’s choice 
(n = 111) 
Any grade Grade 3–4 Any grade Grade 3–4 





















































































aIncludes 1 grade 5 event of pneumonia.  
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Supplemental Figure 1. CONSORT diagram.  
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Supplemental Figure 2. Treatment effect on overall survival by subgroup for the overall intent-to-treat population.  
 
aStratification factor. 
Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HPV, human papillomavirus;  
HR, hazard ratio; IC, investigator’s choice; Nivo, nivolumab.   
21 
 
This article is protected by copyright. All rights reserved.
